Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy

Biochemical Pharmacology

Volumn 80, Issue 12, 2010, Pages 1801-1815

  Cerella, Claudia ^a   Sobolewski, Cyril ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Cancer; Cyclooxygenases; Gene expression; Inflammation; Natural compounds

Indexed keywords

11,14,17 ICOSATRIENOIC ACID; APIGENIN; BROMELAIN; CHRYSIN; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIALLYL TRISULFIDE; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; FISETIN; GENISTEIN; GLUCOSAMINE; HYDROXYTYROSOL; ICOSAPENTAENOIC ACID; KAEMPFEROL; MANGIFERIN; OLEUROPEIN; OMEGA 3 FATTY ACID; PHYTOALEXIN; RESVERATROL; SCHIZANDRIN B; SECOIRIDOID; SULFORAPHANE; TYROSOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; DRUG TARGETING; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA STABILITY; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 78049438246     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.050     Document Type: Review

References (145)

1. Kis B., Snipes J.A., Isse T., Nagy K., Busija D.W. Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 2003, 23:1287-1292.
2. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002, 99:13926-13931.
3. Martel-Pelletier J., Pelletier J.P., Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003, 33:155-167.
4. Zhang L., Bertucci A.M., Smith K.A., Xu L., Datta S.K. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum 2007, 56:4132-4141.
5. Giulietti A., van Etten E., Overbergh L., Stoffels K., Bouillon R., Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile, 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007, 77:47-57.
6. Beyan H., Goodier M.R., Nawroly N.S., Hawa M.I., Bustin S.A., Ogunkolade W.B., et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes 2006, 55:3439-3445.
7. Mino T., Sugiyama E., Taki H., Kuroda A., Yamashita N., Maruyama M., et al. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis Rheum 1998, 41:2004-2013.
8. Cao Y., Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002, 190:279-286.
9. Sobolewski C., Cerella C., Dicato M., Ghibelli L., Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010, 2010:215158.
10. Brown J.R., DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23:2840-2855.
11. Ogino S., Kirkner G.J., Nosho K., Irahara N., Kure S., Shima K., et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008, 14:8221-8227.
12. Cai Y., Lee Y.F., Li G., Liu S., Bao B.Y., Huang J., et al. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J Cancer 2008, 123:195-201.
13. Aparicio Gallego G., Diaz Prado S., Jimenez Fonseca P., Garcia Campelo R., Cassinello Espinosa J., Anton Aparicio L.M. Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol 2007, 9:694-702.
14. Zhao X., Goswami M., Pokhriyal N., Ma H., Du H., Yao J., et al. Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res 2008, 68:467-475.
15. Sucic M., Boban D., Markovic-Glamocak M., Jakic-Razumovic J., Vrbanec D., Ries S., et al. Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases. Breast 2003, 12:51-57.
16. Langenbach R., Loftin C., Lee C., Tiano H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 1999, 58:1237-1246.
17. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
18. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708.
19. Tiano H.F., Loftin C.D., Akunda J., Lee C.A., Spalding J., Sessoms A., et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002, 62:3395-3401.
20. Akunda J.K., Chun K.S., Sessoms A.R., Lao H.C., Fischer S.M., Langenbach R. Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure. Mol Carcinog 2007, 46:354-362.
21. Sarkar F.H., Adsule S., Li Y., Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007, 7:599-608.
22. Bernard M.P., Bancos S., Sime P.J., Phipps R.P. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 2008, 14:2051-2060.
23. Marnett L.J. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009, 49:265-290.
24. Davenport H.W. Damage to the Gastric Mucosa: Effects of Salicylates and Stimulation. Gastroenterology 1965, 49:189-196.
25. Seibert K., Masferrer J.L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994, 4:17-23.
26. Gottlieb S. COX 2 inhibitors may increase risk of heart attack. BMJ 2001, 323:471.
27. De Smet B.D., Fendrick A.M., Stevenson J.G., Bernstein S.J. Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited. J Gen Intern Med 2006, 21:694-697.
28. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007, 50:470-479.
29. Rouzer C.A., Marnett L.J. Cyclooxygenases: structural and functional insights. J Lipid Res 2009, 50 Suppl::S29-34.
30. Surh Y.J., Kundu J.K. Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives. Arch Pharm Res 2005, 28:1-15.
31. Eisinger A.L., Prescott S.M., Jones D.A., Stafforini D.M. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat 2007, 82:147-154.
32. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002, 68-69:95-114.
33. Chun K.S., Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100.
34. Lee S.K., Hong C.H., Huh S.K., Kim S.S., Oh O.J., Min H.Y., et al. Suppressive effect of natural sesquiterpenoids on inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) activity in mouse macrophage cells. J Environ Pathol Toxicol Oncol 2002, 21:141-148.
35. Kundu J.K., Chun K.S., Kim S.O., Surh Y.J. Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors 2004, 21:33-39.
36. Kundu J.K., Na H.K., Chun K.S., Kim Y.K., Lee S.J., Lee S.S., et al. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J Nutr 2003, 133:3805S-3810S.
37. Shrotriya S., Kundu J.K., Na H.K., Surh Y.J. Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling. Cancer Res 2010, 70:1932-1940.
38. Kundu J.K., Chang E.J., Fujii H., Sun B., Surh Y.J. Oligonol inhibits UVB-induced COX-2 expression in HR-1 hairless mouse skin-AP-1 and C/EBP as potential upstream targets. Photochem Photobiol 2008, 84:399-406.
39. Fernau N.S., Fugmann D., Leyendecker M., Reimann K., Grether-Beck S., Galban S., et al. Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J Biol Chem 2010, 285:3896-3904.
40. Bhatia H.S., Candelario-Jalil E., de Oliveira A.C., Olajide O.A., Martinez-Sanchez G., Fiebich B.L. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Arch Biochem Biophys 2008, 477:253-258.
41. Gong Y., Xue B., Jiao J., Jing L., Wang X. Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 2008, 107:779-788.
42. Subbaramaiah K., Lin D.T., Hart J.C., Dannenberg A.J. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001, 276:12440-12448.
43. Newton R., Seybold J., Kuitert L.M., Bergmann M., Barnes P.J. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 1998, 273:32312-32321.
44. Harper K.A., Tyson-Capper A.J. Complexity of COX-2 gene regulation. Biochem Soc Trans 2008, 36:543-545.
45. Song S.H., Jong H.S., Choi H.H., Inoue H., Tanabe T., Kim N.K., et al. Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Res 2001, 61:4628-4635.
46. Akhtar M., Cheng Y., Magno R.M., Ashktorab H., Smoot D.T., Meltzer S.J., et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001, 61:2399-2403.
47. Yamaguchi K., Lantowski A., Dannenberg A.J., Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 2005, 280:32569-32577.
48. Deng W.G., Zhu Y., Wu K.K. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 2003, 278:4770-4777.
49. Cok S.J., Morrison A.R. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 276:23179-23185.
50. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression, The role of the 3'-untranslated region. J Biol Chem 2000, 275:11750-11757.
51. Mazumder B., Li X., Barik S. Translation control: a multifaceted regulator of inflammatory response. J Immunol 2010, 184:3311-3319.
52. Hall-Pogar T., Zhang H., Tian B., Lutz C.S. Alternative polyadenylation of cyclooxygenase-2. Nucleic Acids Res 2005, 33:2565-2579.
53. Hall-Pogar T., Liang S., Hague L.K., Lutz C.S. Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3'-UTR. RNA 2007, 13:1103-1115.
54. Newton R., Seybold J., Liu S.F., Barnes P.J. Alternate COX-2 transcripts are differentially regulated: implications for post-transcriptional control. Biochem Biophys Res Commun 1997, 234:85-89.
55. Lukiw W.J., Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997, 50:937-945.
56. Mukhopadhyay D., Houchen C.W., Kennedy S., Dieckgraefe B.K., Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 2003, 11:113-126.
57. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001, 108:1657-1665.
58. Boutaud O., Dixon D.A., Oates J.A., Sawaoka H. Tristetraprolin binds to the COX-2 mRNA 3' untranslated region in cancer cells. Adv Exp Med Biol 2003, 525:157-160.
59. Dixon D.A., Balch G.C., Kedersha N., Anderson P., Zimmerman G.A., Beauchamp R.D., et al. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 2003, 198:475-481.
60. Lim S.J., Kim H.J., Kim J.Y., Park K., Lee C.M. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007, 26:229-234.
61. Denkert C., Weichert W., Winzer K.J., Muller B.M., Noske A., Niesporek S., et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004, 10:5580-5586.
62. Deleault K.M., Skinner S.J., Brooks S.A. Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 2008, 45:13-24.
63. Hau H.H., Walsh R.J., Ogilvie R.L., Williams D.A., Reilly C.S., Bohjanen P.R. Tristetraprolin recruits functional mRNA decay complexes to ARE sequences. J Cell Biochem 2007, 100:1477-1492.
64. Anant S., Houchen C.W. HuR and TTP: two RNA binding proteins that deliver message from the 3' end. Gastroenterology 2009, 136:1495-1498.
65. Young L.E., Sanduja S., Bemis-Standoli K., Pena E.A., Price R.L., Dixon D.A. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 2009, 136:1669-1679.
66. Sanduja S., Kaza V., Dixon D.A. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging (Albany NY) 2009, 1:803-817.
67. Brennan S.E., Kuwano Y., Alkharouf N., Blackshear P.J., Gorospe M., Wilson G.M. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res 2009, 69:5168-5176.
68. Carballo E., Lai W.S., Blackshear P.J. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 2000, 95:1891-1899.
69. Piecyk M., Wax S., Beck A.R., Kedersha N., Gupta M., Maritim B., et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 2000, 19:4154-4163.
70. Dember L.M., Kim N.D., Liu K.Q., Anderson P. Individual RNA recognition motifs of TIA-1 and TIAR have different RNA binding specificities. J Biol Chem 1996, 271:2783-2788.
71. Gueydan C., Droogmans L., Chalon P., Huez G., Caput D., Kruys V. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA. J Biol Chem 1999, 274:2322-2326.
72. Jin S.H., Kim T.I., Yang K.M., Kim W.H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol 2007, 558:14-20.
73. Doller A., Huwiler A., Muller R., Radeke H.H., Pfeilschifter J., Eberhardt W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 2007, 18:2137-2148.
74. Parker M.T., Gerner E.W. Polyamine-mediated post-transcriptional regulation of COX-2. Biochimie 2002, 84:815-819.
75. Chen K.Y. An 18000-dalton protein metabolically labeled by polyamines in various mammalian cell lines. Biochim Biophys Acta 1983, 756:395-402.
76. Bachrach U. Polyamines and cancer: minireview article. Amino Acids 2004, 26:307-309.
77. Reddy B.S. Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem 2007, 42:213-225.
78. Strillacci A., Griffoni C., Sansone P., Paterini P., Piazzi G., Lazzarini G., et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009, 315:1439-1447.
79. Chakrabarty A., Tranguch S., Daikoku T., Jensen K., Furneaux H., Dey S.K. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci U S A 2007, 104:15144-15149.
80. Tanaka T., Haneda S., Imakawa K., Sakai S., Nagaoka K. A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 2009, 77:181-187.
81. Hiroki E., Akahira J., Suzuki F., Nagase S., Ito K., Suzuki T., et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010, 101:241-249.
82. Ji Y., He Y., Liu L., Zhong X. MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett 2010, 584:961-967.
83. Shanmugam N., Reddy M.A., Natarajan R. Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem 2008, 283:36221-36233.
84. Abdelmohsen K., Srikantan S., Kuwano Y., Gorospe M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 2008, 105:20297-20302.
85. Abdelmohsen K., Kim M.M., Srikantan S., Mercken E.M., Brennan S.E., Wilson G.M., et al. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 2010, 9.
86. Guo X., Wu Y., Hartley R.S. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol 2009, 6:575-583.
87. Yang L., Belaguli N., Berger D.H. MicroRNA and colorectal cancer. World J Surg 2009, 33:638-646.
88. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007, 179:5082-5089.
89. Bazzoni F., Rossato M., Fabbri M., Gaudiosi D., Mirolo M., Mori L., et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A 2009, 106:5282-5287.
90. Perry M.M., Moschos S.A., Williams A.E., Shepherd N.J., Larner-Svensson H.M., Lindsay M.A. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008, 180:5689-5698.
91. Otto J.C., DeWitt D.L., Smith W.L. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 1993, 268:18234-18242.
92. Sevigny M.B., Li C.F., Alas M., Hughes-Fulford M. Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett 2006, 580:6533-6536.
93. Mbonye U.R., Yuan C., Harris C.E., Sidhu R.S., Song I., Arakawa T., et al. Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008, 283:8611-8623.
94. Mbonye U.R., Song I. Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep 2009, 42:552-560.
95. Tian J., Kim S.F., Hester L., Snyder S.H. S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity. Proc Natl Acad Sci U S A 2008, 105:10537-10540.
96. Parfenova H., Balabanova L., Leffler C.W. Posttranslational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol 1998, 274:C72-C81.
97. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Garner C., Seibert K., Marnett L.J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998, 280:1268-1270.
98. Jang B.C., Sung S.H., Park J.G., Park J.W., Bae J.H., Shin D.H., et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem 2007, 282:27622-27632.
99. Van Der Ouderaa F.J., Buytenhek M., Nugteren D.H., Van Dorp D.A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 1980, 109:1-8.
100. Groeger A.L., Cipollina C., Cole M.P., Woodcock S.R., Bonacci G., Rudolph T.K., et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol 2010, 6:433-441.
101. Chen C. COX-2s new role in inflammation. Nat Chem Biol 2010, 6:401-402.
102. Duvoix A., Delhalle S., Blasius R., Schnekenburger M., Morceau F., Fougere M., et al. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem Pharmacol 2004, 68:1101-1111.
103. Folmer F., Blasius R., Morceau F., Tabudravu J., Dicato M., Jaspars M., et al. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem Pharmacol 2006, 71:1206-1218.
104. Schumacher M., Cerella C., Eifes S., Chateauvieux S., Morceau F., Jaspars M., et al. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B activation through proteasome inhibition and induces apoptotic cell death. Biochem Pharmacol 2010, 79:610-622.
105. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001, 480-481:243-268.
106. Zhang F., Altorki N.K., Mestre J.R., Subbaramaiah K., Dannenberg A.J. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999, 20:445-451.
107. Huang M.T., Lysz T., Ferraro T., Abidi T.F., Laskin J.D., Conney A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991, 51:813-819.
108. Chun K.S., Keum Y.S., Han S.S., Song Y.S., Kim S.H., Surh Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 2003, 24:1515-1524.
109. Kang G., Kong P.J., Yuh Y.J., Lim S.Y., Yim S.V., Chun W., et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 2004, 94:325-328.
110. Sharma C., Kaur J., Shishodia S., Aggarwal B.B., Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006, 228:1-15.
111. Cho J.W., Park K., Kweon G.R., Jang B.C., Baek W.K., Suh M.H., et al. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005, 37:186-192.
112. Camacho-Barquero L., Villegas I., Sanchez-Calvo J.M., Talero E., Sanchez-Fidalgo S., Motilva V., et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007, 7:333-342.
113. Yu Z., Shah D.M. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. Gynecol Oncol 2007, 106:541-548.
114. Tsatsanis C., Androulidaki A., Venihaki M., Margioris A.N. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38:1654-1661.
115. Jang M., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 1999, 25:65-77.
116. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998, 273:21875-21882.
117. Park O.J., Surh Y.J. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett 2004, 150:43-56.
118. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164:6509-6519.
119. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 1997, 52:465-472.
120. Barthelman M., Bair W.B., Stickland K.K., Chen W., Timmermann B.N., Valcic S., et al. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998, 19:2201-2204.
121. Mutoh M., Takahashi M., Fukuda K., Matsushima-Hibiya Y., Mutoh H., Sugimura T., et al. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 2000, 21:959-963.
122. Liang Y.C., Huang Y.T., Tsai S.H., Lin-Shiau S.Y., Chen C.F., Lin J.K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 1999, 20:1945-1952.
123. Woo E.R., Pokharel Y.R., Yang J.W., Lee S.Y., Kang K.W. Inhibition of nuclear factor-kappaB activation by 2',8" -biapigenin. Biol Pharm Bull 2006, 29:976-980.
124. Srivastava J.K., Pandey M., Gupta S. Chamomile: a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci 2009, 85:663-669.
125. Woo K.J., Jeong Y.J., Inoue H., Park J.W., Kwon T.K. Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNA-binding activity. FEBS Lett 2005, 579:705-711.
126. Suh Y., Afaq F., Johnson J.J., Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis 2009, 30:300-307.
127. Moon D.O., Kim M.O., Kang S.H., Choi Y.H., Kim G.Y. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett 2009, 274:132-142.
128. Bhui K., Prasad S., George J., Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett 2009, 282:167-176.
129. Palozza P., Serini S., Maggiano N., Tringali G., Navarra P., Ranelletti F.O., et al. beta-Carotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells. J Nutr 2005, 135:129-136.
130. Guo L.Y., Hung T.M., Bae K.H., Shin E.M., Zhou H.Y., Hong Y.N., et al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol 2008, 591:293-299.
131. Corona G., Deiana M., Incani A., Vauzour D., Dessi M.A., Spencer J.P. Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. Biochem Biophys Res Commun 2007, 362:606-611.
132. Tong X., Van Dross R.T., Abu-Yousif A., Morrison A.R., Pelling J.C. Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition. Mol Cell Biol 2007, 27:283-296.
133. Peng G., Dixon D.A., Muga S.J., Smith T.J., Wargovich M.J. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006, 45:309-319.
134. Annabi B., Currie J.C., Moghrabi A., Beliveau R. Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res 2007, 31:1277-1284.
135. Cao H., Kelly M.A., Kari F., Dawson H.D., Urban J.F., Coves S., et al. Green tea increases anti-inflammatory tristetraprolin and decreases pro-inflammatory tumor necrosis factor mRNA levels in rats. J Inflamm (Lond) 2007, 4:1.
136. Tsang W.P., Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010, 21:140-146.
137. Habbel P., Weylandt K.H., Lichopoj K., Nowak J., Purschke M., Wang J.D., et al. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. World J Gastroenterol 2009, 15:1079-1084.
138. Janakiram N.B., Rao C.V. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 2009, 9:565-579.
139. Bommareddy A., Zhang X., Schrader D., Kaushik R.S., Zeman D., Matthees D.P., et al. Effects of dietary flaxseed on intestinal tumorigenesis in Apc(Min) mouse. Nutr Cancer 2009, 61:276-283.
140. Fradet V., Cheng I., Casey G., Witte J.S. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009, 15:2559-2566.
141. Lee C.Y., Sit W.H., Fan S.T., Man K., Jor I.W., Wong L.L., et al. The cell cycle effects of docosahexaenoic acid on human metastatic hepatocellular carcinoma proliferation. Int J Oncol 2010, 36:991-998.
142. Jin X.J., Kim E.J., Oh I.K., Kim Y.K., Park C.H., Chung J.H. Prevention of UV-induced skin damages by 11,14,17-eicosatrienoic acid in hairless mice in vivo. J Korean Med Sci 2010, 25:930-937.
143. Lim K., Han C., Dai Y., Shen M., Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 2009, 8:3046-3055.
144. Abramson S.B. The role of COX-2 produced by cartilage in arthritis. Osteoarthritis Cartilage 1999, 7:380-381.
145. Hong H., Park Y.K., Choi M.S., Ryu N.H., Song D.K., Suh S.I., et al. Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride. J Dermatol Sci 2009, 56:43-50.